Back to mobile site
Get it on Google Play

Vanda reports positive Phase III results for HETLIOZ in sleep disorder

September 29, 2026 7:10 PM EDT Send to a Friend
Vanda Pharmaceuticals (NASDAQ: VNDA) announced positive topline results from a Phase III study of HETLIOZ (tasimelteon) 20 mg in adults ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login